RHONEMA Stock Overview
An investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rhone Ma Holdings Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.68 |
| 52 Week High | RM 0.80 |
| 52 Week Low | RM 0.63 |
| Beta | 0.24 |
| 11 Month Change | -0.74% |
| 3 Month Change | -5.59% |
| 1 Year Change | -2.17% |
| 33 Year Change | -3.57% |
| 5 Year Change | -2.17% |
| Change since IPO | -14.66% |
Recent News & Updates
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Jun 19
We Think Some Shareholders May Hesitate To Increase Rhone Ma Holdings Berhad's (KLSE:RHONEMA) CEO Compensation
Jun 04Recent updates
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Jun 19We Think Some Shareholders May Hesitate To Increase Rhone Ma Holdings Berhad's (KLSE:RHONEMA) CEO Compensation
Jun 04Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Affirmed Its Dividend Of MYR0.01
May 02Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Apr 18Rhone Ma Holdings Berhad (KLSE:RHONEMA) Is Paying Out A Dividend Of MYR0.01
Dec 18Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Announced A Dividend Of RM0.01
May 02We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Rhone Ma Holdings Berhad's (KLSE:RHONEMA) CEO For Now
Jul 19Does Rhone Ma Holdings Berhad (KLSE:RHONEMA) Have A Healthy Balance Sheet?
Jun 07Is Rhone Ma Holdings Berhad (KLSE:RHONEMA) A Risky Investment?
Mar 09Introducing Rhone Ma Holdings Berhad (KLSE:RHONEMA), A Stock That Climbed 32% In The Last Year
Feb 02
Can Rhone Ma Holdings Berhad's (KLSE:RHONEMA) Weak Financials Pull The Plug On The Stock's Current Momentum On Its Share Price?
Jan 12Are Rhone Ma Holdings Berhad's (KLSE:RHONEMA) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 06Shareholder Returns
| RHONEMA | MY Pharmaceuticals | MY Market | |
|---|---|---|---|
| 7D | -0.7% | 0.2% | 0.09% |
| 1Y | -2.2% | -0.4% | 9.5% |
Return vs Industry: RHONEMA underperformed the MY Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: RHONEMA underperformed the MY Market which returned 9.5% over the past year.
Price Volatility
| RHONEMA volatility | |
|---|---|
| RHONEMA Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in MY Market | 10.4% |
| 10% least volatile stocks in MY Market | 2.5% |
Stable Share Price: RHONEMA has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: RHONEMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 205 | I-Ie Lim | www.rhonema.com |
Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia. The company provides diagnostic laboratory analysis and consultation services to veterinary, agriculture, and food industries; tests and diagnostics services for human healthcare; and veterinary advisory services. It also conducts research and development in biotechnology; distributes human healthcare and related products; wholesales and distributes pharmaceutical and veterinary products, including animal feeds; undertakes research and development activities related to animal health, food safety, and agriculture; and distributes and supplies food ingredients.
Rhone Ma Holdings Berhad Fundamentals Summary
| RHONEMA fundamental statistics | |
|---|---|
| Market cap | RM 149.33m |
| Earnings (TTM) | RM 12.49m |
| Revenue (TTM) | RM 214.31m |
12.0x
P/E Ratio0.7x
P/S RatioIs RHONEMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHONEMA income statement (TTM) | |
|---|---|
| Revenue | RM 214.31m |
| Cost of Revenue | RM 155.27m |
| Gross Profit | RM 59.05m |
| Other Expenses | RM 46.55m |
| Earnings | RM 12.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.056 |
| Gross Margin | 27.55% |
| Net Profit Margin | 5.83% |
| Debt/Equity Ratio | 13.4% |
How did RHONEMA perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield27%
Payout RatioDoes RHONEMA pay a reliable dividends?
See RHONEMA dividend history and benchmarks| Rhone Ma Holdings Berhad dividend dates | |
|---|---|
| Ex Dividend Date | Dec 13 2024 |
| Dividend Pay Date | Dec 27 2024 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 33 days |
Does RHONEMA pay a reliable dividends?
See RHONEMA dividend history and benchmarks